VCYT
Veracyte Inc (VCYT)
Healthcare • NASDAQ • $40.42-0.83%
- Symbol
- VCYT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Price
- $40.42
- Daily Change
- -0.83%
- Market Cap
- $3.23B
- Trailing P/E
- 37.43
- Forward P/E
- 21.87
- 52W High
- $50.71
- 52W Low
- $22.61
- Analyst Target
- $47.82
- Dividend Yield
- N/A
- Beta
- 1.89
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Company websiteResearch VCYT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.